HLS Therapeutics (HLS Therapeutics) Operating Cash Flow per Share : $0.49 (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Operating Cash Flow per Share?

HLS Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $0.12. HLS Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.49.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of HLS Therapeutics was -7.50% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for HLS Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

HLTRF' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -52.2 Med: 4.3 Max: 83
Current: 20.3

During the past 13 years, HLS Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 83.00% per year. The lowest was -52.20% per year. And the median was 4.30% per year.

HLTRF's 3-Year OCF Growth Rate is ranked better than
66.75% of 806 companies
in the Drug Manufacturers industry
Industry Median: 8.1 vs HLTRF: 20.30

HLS Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for HLS Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Operating Cash Flow per Share Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.90

0.30

0.51

0.52

0.49

HLS Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.11	0.12	0.08	0.17	0.12

Competitive Comparison of HLS Therapeutics's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Price-to-Operating-Cash-Flow falls into.

HLS Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

HLS Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	15.789	/	32.263
	=	0.49

HLS Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	3.734	/	32.094
	=	0.12

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49

HLS Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (HLS Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA • 03-21-2013